iX Biopharma (SGX:42C) Total Liabilities : S$9.57 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is iX Biopharma Total Liabilities?

iX Biopharma's Total Liabilities for the quarter that ended in Dec. 2024 was S$9.57 Mil.

iX Biopharma's quarterly Total Liabilities declined from Dec. 2023 (S$10.65 Mil) to Jun. 2024 (S$10.28 Mil) and declined from Jun. 2024 (S$10.28 Mil) to Dec. 2024 (S$9.57 Mil).

iX Biopharma's annual Total Liabilities increased from Jun. 2022 (S$8.77 Mil) to Jun. 2023 (S$9.08 Mil) and increased from Jun. 2023 (S$9.08 Mil) to Jun. 2024 (S$10.28 Mil).

iX Biopharma Total Liabilities Historical Data

The historical data trend for iX Biopharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iX Biopharma Total Liabilities Chart

iX Biopharma Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Total Liabilities

Get a 7-Day Free Trial

6.81

7.15

8.77

9.08

10.28

iX Biopharma Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Liabilities	Get a 7-Day Free Trial															8.54	9.08	10.65	10.28	9.57

iX Biopharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

iX Biopharma's Total Liabilities for the fiscal year that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	7.381	+	(2.324	+	5.5511151231258E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0.04	+	0.539)
	=	10.28

Total Liabilities	=	Total Assets (A: Jun. 2024 )	-	Total Equity (A: Jun. 2024 )
	=	14.624	-	4.34
	=	10.28

iX Biopharma's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	7.148	+	(1.969	+	0.014000000000001
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0.539)
	=	9.57

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	13.084	-	3.514
	=	9.57

iX Biopharma Total Liabilities Related Terms

Thank you for viewing the detailed overview of iX Biopharma's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

iX Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » iX Biopharma Ltd (SGX:42C) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994

Website

https://www.ixbiopharma.com

iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.

iX Biopharma Headlines

No Headlines